Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Omega Therapeutics (OMGA) presents a compelling investment opportunity due to its pioneering approach to medicine with programmable epigenomic-controller mRNA medicines. The company's unique Next-Gen mRNA Platform addresses the limitations of other mRNA therapies, promising fewer side effects and the ability to target previously undruggable diseases. A recent collaboration with Novo Nordisk, a pharma giant, to develop an obesity drug using Omega's platform speaks volumes about the company's technology potential and opens doors for future deals. Analysts at Wedbush and H.C. Wainwright share the optimism, with $12.00 price targets and buy ratings, but the potential is considered much bigger. Compared to established mRNA players, Omega trades at a significantly lower price, offering tremendous potential for future growth. The company has a diverse pipeline of promising candidates across various disease areas, and it is listed on the NASDAQ-GS, a market reserved for established and respected companies. Additionally, Omega is backed by Flagship Pioneering, the venture capital firm that propelled Moderna to success, signaling confidence in Omega's potential to disrupt the healthcare landscape. The company's digital and AI-based computational engine enables rapid design and development of therapeutic candidates, accelerating discovery and preclinical development. Omega's versatile platform could tackle not just fatty liver, but a variety of diseases. Despite a recent dip in share price, astute investors see this as a buying opportunity, with potential for a rapid climb past $10 and long-term prospects extending far beyond a $60 share price. Omega Therapeutics has the potential for significant growth, similar to other mRNA companies of the past. The company's innovative approach to developing a new class of programmable epigenomic mRNA medicines has garnered attention and excitement within the biotechnology industry. With the upcoming release of updated clinical data and the initiation of expansion cohorts, Omega Therapeutics is on the brink of potentially revolutionizing cancer treatment and solidifying its position as a leader in precision epigenomic control. The company's groundbreaking approach, promising data, and industry partnerships paint a strong picture, attracting substantial and ongoing investment. Omega's future looks bright, and it is considered one of the companies that is setting up for significant gains in 2024, fueled by multibillion-dollar deals, upbeat clinical results, and cutting-edge medical advances like CRISPR gene-editing hitting prime-time and programmable epigenomic-controllers being a safer option. Therefore, Omega Therapeutics (OMGA) represents an attractive investment opportunity with the potential for significant growth and a unique position in the burgeoning field of programmable epigenomic-controller mRNA medicines.
Omega Therapeutics is a leading company in the field of programmable epigenomic-controller mRNA medicine for several compelling reasons:
Remember, the patent landscape is constantly evolving, so staying updated on patent filings and granted inventions in this field remains crucial for tracking the potential leaders.
“The Company plans to present a corporate update on January 8, 2024 at the 2024 J.P. Morgan Healthcare Conference. A copy of the presentation that will be used is furnished as Exhibit 99.2 to this Current Report on Form 8-K”
Not sure there will be another PR.
Thanks for the laugh. I was so upset, that I didn't even notice the price, until you brought it up. 🫣
Investment Philosophy: I can't miss what I never had, BUT, I can really miss what I used to have.
Whatever helps you sleep at night.
lol, That money has flipped over so many times since that day 2 months ago. Prrreeetttty sure I'm ahead. 😜
Dead money becomes a loss as Opportunity Cost are figured in.
Bought in @ $1.84. Today was a big surprise but it does have a $12 price target.
This puppy has a ways to go.
Omega Therapeutics Stock Surges 99% Following Pact with Novo Nordisk to Treat obesity
Published: Jan. 4, 2024 at 7:06 a.m. ET
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
January 04, 2024 05:59 ET
| Source: Novo Nordisk A/S
Share
Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity management
Cellarity collaboration will build upon initial work and engage the company’s platform to develop a small molecule therapy in metabolic dysfunction-associated steatohepatitis (MASH)
First two research programmes signed under existing partnership between Novo Nordisk and Flagship Pioneering
Novo Nordisk will reimburse R&D costs and each company and Flagship’s Pioneering Medicines are eligible to receive up to 532 million US dollars in upfront and milestone payments, as well as tiered royalties
Bagsværd, Denmark, Cambridge, Mass., and Somerville, Mass. 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc.
https://www.globenewswire.com/news-release/2024/01/04/2803788/0/en/Novo-Nordisk-enters-into-research-collaborations-with-Omega-Therapeutics-and-Cellarity-on-novel-treatment-approaches-for-cardiometabolic-diseases.html
Omega Therapeutics Stock Surges 99% Following Pact with Novo Nordisk to Treat obesity
Published: Jan. 4, 2024 at 7:06 a.m. ET
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
January 04, 2024 05:59 ET
| Source: Novo Nordisk A/S
Share
Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity management
Cellarity collaboration will build upon initial work and engage the company’s platform to develop a small molecule therapy in metabolic dysfunction-associated steatohepatitis (MASH)
First two research programmes signed under existing partnership between Novo Nordisk and Flagship Pioneering
Novo Nordisk will reimburse R&D costs and each company and Flagship’s Pioneering Medicines are eligible to receive up to 532 million US dollars in upfront and milestone payments, as well as tiered royalties
Bagsværd, Denmark, Cambridge, Mass., and Somerville, Mass. 4 January, 2024 – Novo Nordisk, Omega Therapeutics, Inc.
https://www.globenewswire.com/news-release/2024/01/04/2803788/0/en/Novo-Nordisk-enters-into-research-collaborations-with-Omega-Therapeutics-and-Cellarity-on-novel-treatment-approaches-for-cardiometabolic-diseases.html
Flagship's Pioneering Medicines will be eligible to receive up to $532 million in upfront and milestone payments, along with tiered royalties. MASH is a chronic liver disease with high unmet patient need for which there is currently no treatment. Omega's stock soared 25% premarket.
Out now that I got back even. Don't see any catalyst any time soon.
Agreed. Almost sold on the news yesterday, just from fatigue, but held. Of course, I didn't expect for that .30 drop.
Will probably to continue to hold and add along the way.
That presentation they gave yesterday in Berlin, might just bear some fruit.
So much of their work is in the early stage time frame, that I wonder about a buyout of the technology.
I'll look into their history in that regards.
Would like to have a crystal ball as to the time frame on this puppy
Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
October 31 2023 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced new preclinical data showcasing simultaneous and coordinated pre-transcriptional control of multiple genes co-located in an insulated genomic domain (IGD) by a single epigenomic controller (EC) at the 11th International mRNA Health Conference taking place in Berlin, Germany, October 31 – November 2, 2023.
“These new preclinical data show that, through deep understanding of disease biology and genomic architecture, our OMEGA platform is able to design a programmable mRNA candidate capable of multiplexing to pre-transcriptionally control the expression of multiple genes in preclinical models,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega Therapeutics. “By targeting a genomic locus containing a cluster of cytokine genes, we can precisely modulate immune activity to elicit a meaningful anti-inflammatory response. The potential applications of this strategy extend beyond any single disease and highlight the broad potential of precision epigenomic control.”
Details for the poster presentation:
Title: Design and Characterization of a Programmable Epigenomic Controller Demonstrating
Multiplexed Targeting of the CXCL1-8 Gene Cluster for Treatment of Inflammatory Disorders
Poster #: 79
Session information: Flash Poster Talks / New Company Introductions Session
Date and Time: Tuesday, October 31, 2023, from 4:00 pm to 5:00 pm CET
Key Findings:
Treatment of human lung fibroblasts with CXCL1-8-targeting ECs correlated with corresponding decrease in gene expression of multiple CXCL chemokines
EC-induced changes in the epigenetic profiles of the CXCL1-8 genes were associated with decreased binding of NF-kB
Human lung fibroblasts treated with a single CXCL-EC engineered to modulate the epigenetic profiles of the CXCL1-8 gene cluster showed downregulation of both mRNA and protein levels of CXCL1, 2 and 8
Cells treated with a CXCL-EC showed decreased ability to support neutrophil migration in vitro
In a mouse model of lung inflammation, single administration of a mouse surrogate CXCL-EC resulted in decreased recruitment of neutrophils and B and T cells into bronchoalveolar fluid
The poster will be available on the Omega website at https://omegatherapeutics.com/science/publications at the same time as the presentation.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables controlled epigenomic modulation of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
For more information, visit omegatherapeutics.com, or follow us on X (formerly Twitter) and LinkedIn.
Mirrow trade at 16:00. 15,7785 X 2 @ 1.37
Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
OMGA: https://www.nasdaq.com/articles/omega-therapeutics-omga-price-target-increased-by-10.98-to-13.26
Confirmation of Moderna Founder link.
It appears that they are investors, but I can't find it in the filings?
Trying to find the ties in OMGA filings???
This is the guy who is a co-founder of Moderna:
https://www.flagshippioneering.com/people
If you click on "Companies", you find OmegaTh.
Some decent buying on the drop....so far.
He has been somewhat of an Oracle on those. Fingers Crossed, he still has his MoJo. :)
Monk will be posting the new low tonight
Aholes. I doubled up @ 1.52. Avg. 1.635 F'em. It's going to go sooner or later.
OMGA: Holding the 1.7-1.75 area ovreall, with short dips.
OMGA: Shorts keep trying to pull it down, but so far, it snaps right back.
One of the things I like is, it's been at twice 1.72 in the last month and above $6 in the last 3 months.
$1.56 52wk low
$11.98 52wk high
I don't think this one is going to linger anywhere near a dollar for long.
Lots of room to move north from here
OMGA: Check this out. A Buy of 36,485 @ 16:00 and a mirror trade 2 secs. later. $62,754. (@ $1.72)
Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023
October 11 2023 - 04:00PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data demonstrating the potential of epigenomic controllers for the treatment of inflammatory and fibrotic liver diseases at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14.
“Our OMEGA platform enables us to rationally and rapidly design epigenomic controllers to bidirectionally tune the expression of one or multiple genes pre-transcriptionally,” said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. “These preclinical data demonstrate the potential of programmable mRNA development candidates to controllably upregulate the expression of a single gene to drive liver regeneration in models of fibrosis, as well as the ability to simultaneously downregulate the expression of multiple genes linked to inflammatory liver diseases with a single epigenomic controller. Together, these findings underscore the versatile capabilities of our OMEGA platform and the potential of precision epigenomic control to address a broad range of diseases.”
Details for the poster presentations are as follows:
Title: Targeting CXCL9/CXCL10/CXCL11 using novel epigenomic controllers for the treatment of inflammatory liver disease
Poster number: 2621-A
Date and Time: November 11, 2023, from 1:00 p.m. to 2:00 p.m. ET
This poster has been selected by AASLD as a “Poster of Distinction”, having been classified as being in the top 5% of scored poster abstracts and will receive special recognition in the Poster Hall.
Title: Induction of Hepatocyte Nuclear Factor 4 alpha (HNF4a) using novel epigenomic controllers
Poster number: 3444-A
Date and Time: November 12, 2023, from 1:00 p.m. to 2:00 p.m. ET
The posters will be made available on the Omega website at https://omegatherapeutics.com/our-science/#publications-research at the same time as the presentations.
About the OMEGA Platform
The OMEGA platform leverages the Company’s deep understanding of gene regulation, genomic architecture and epigenetic mechanisms to design programmable epigenomic mRNA medicines that precisely target and modulate gene expression at the pre-transcriptional level. Combining a biology-first approach and world-class data science capabilities with rational drug design and customized delivery, the OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range. Omega’s investigational programmable mRNA medicines, Epigenomic Controllers, target specific genomic loci within insulated genomic domains with high specificity to durably tune single or multiple genes to treat and cure diseases through unprecedented precision epigenomic control.
About Omega Therapeutics
Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables controlled epigenomic modulation of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
For more information, visit omegatherapeutics.com, or follow us on X (formerly Twitter) and LinkedIn.
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
68
|
Created
|
10/09/23
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |